ClinicalTrials.gg
CompletedNCT02271503Updated Nov 6, 2019

A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease

A Phase 2 interventional study of CD-LD IR and IPX203 180 mg in Parkinson's Disease, sponsored by Impax Laboratories, LLC. Completed at 11 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2019-11-06.

Sponsored by Impax Laboratories, LLC (part of Amneal Pharmaceuticals, Inc.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2016, 10 years 3 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Sep 2017.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc. — 1 open to participants now, 1 under way, none of them phase 3. Parkinson Disease · Amneal Pharmaceuticals, Inc..

Enrollment
11th of 14
26 · median 77
Started
2015
the only one that year
Phase 2
5 of 14
none open now
Registered
10th of 14
by date

Among the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc., this one is the 11th largest by enrollment, is the only one that started in 2015, is one of 5 in phase 2, and was the 10th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc., or all of them as a file.
02

Study summary

This is a randomized, open-label, rater-blinded, multicenter, 3-treatment, 3 period, single-dose crossover study. Approximately 51 qualified immediate-release (IR) CD-LD-experienced advanced Parkinson's disease patients will be randomized to 1 of 3 dosing sequences.

Objectives:

  • Assess the pharmacodynamics and pharmacokinetics (PK) of IPX203 (carbidopa and levodopa) in subjects with advanced Parkinson's disease.
  • Characterize the safety of IPX203 in subjects with advanced Parkinson's disease.
Read the detailed description

IPX203 contains two different drugs called levodopa and carbidopa in one capsule.

  • levodopa turns into a material called 'dopamine' in your brain. The dopamine helps to improve the symptoms of your Parkinson's disease.
  • carbidopa belongs to a group of medicines called 'aromatic amino acid decarboxylase inhibitors'. It helps levodopa work more effectively by slowing the speed at which levodopa is broken down in your body.
03

Conditions studied

  • Parkinson's Disease

Browse trials for

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male or female subjects diagnosed with idiopathic PD with motor complications, who are currently being treated chronically with stable regimens of CD-LD.

Requiring at least 400 mg but not more than 1600 mg LD per day during the waking hours; and at least 100 mg but not more than 250 mg LD from IR CD-LD for the first morning dose.

Dosing frequency of IR CD-LD of at least 4 times daily excluding nighttime dosing.

Have an average of at least 2 hours per day "off" time during the waking hours and at least 1 hour "off" time per day, based on the PD diary collected for 3 consecutive days prior to Visit 1.

Exclusion criteria

Exclusion criteria:

Have used first morning dose of controlled-release (CR) CD-LD or Rytary for at least 4 weeks prior to Visit 1.

Female subjects who are currently breastfeeding or lactating.

Had prior functional neurosurgical treatment for PD (ablation or deep brain stimulation) or if such procedure(s) are planned or anticipated during the study period.

Allergic to study drugs

History of medical conditions or of a prior surgical procedure that would interfere with LD absorption, such as gastrectomy or small-bowel resection.

History of peptic ulcer disease or upper gastrointestinal hemorrhage.

History of narrow angle glaucoma.

History of myocardial infarction with residual atrial, nodal, or ventricular arrhythmias; neuroleptic malignant syndrome; or nontraumatic rhabdomyolysis.

History of psychosis.

Employees or family members of the Investigator, study site, or Sponsor.

Subjects who, in the opinion of the clinical investigator, should not participate in the study.

Based on clinical assessment, subject does not adequately comprehend the terminology needed to complete the PD diary.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
26 participants (actual)

Study arms

  • Other
    Sequence 1

    Subject received a single dose of IPX203 180 mg and/or IPX203 270mg in Period 1, a single dose of CD-LD IR in Period 2, and a single dose of Rytary 145 mg and/or Rytary 195 mg in Period 3.

    Drug: CD-LD IR · Drug: IPX203 180 mg · Drug: IPX203 270 mg · Drug: Rytary 195 mg · Drug: Rytary 145 mg

  • Other
    Sequence 2

    Subject received a single dose of a single dose of CD-LD IR in Period 1, a single dose of Rytary 145 mg and/or Rytary 195 mg in Period 2, and a single dose of IPX203 180 mg and/or IPX203 270mg in Period 3.

    Drug: CD-LD IR · Drug: IPX203 180 mg · Drug: IPX203 270 mg · Drug: Rytary 195 mg · Drug: Rytary 145 mg

  • Other
    Sequence 3

    Subject received a single dose of a single dose of Rytary 145 mg and/or Rytary 195 mg in Period 1, a single dose of IPX203 180 mg and/or IPX203 270mg in Period 2, and a single dose of CD-LD IR in Period 3.

    Drug: CD-LD IR · Drug: IPX203 180 mg · Drug: IPX203 270 mg · Drug: Rytary 195 mg · Drug: Rytary 145 mg

Interventions

  • DrugCD-LD IR

    CD-LD IR containing 25 mg carbidopa and 100 mg levodopa

    Also known as: Sinemet

  • IPX203 containing 45 mg carbidopa and180 mg levodopa

    Also known as: CD-LD ER 180 mg

  • IPX203 containing 67.5 mg carbidopa and 270 mg levodopa

    Also known as: CD-LD ER 270 mg

  • DrugRytary 195 mg

    Rytary 48.75Mg-195Mg Extended-Release Capsule

  • DrugRytary 145 mg

    Rytary 36.25Mg-145Mg Extended-Release Capsule

06

What researchers measure

Primary outcomes

  1. "Off" time per the Assessment of Subject's Motor State

    Time frame: Up to 10 hours

Secondary outcomes

  1. Duration of effect estimated using the timepoint at which an improvement of at least 4 points in the MDS-UPDRS Part III score from predose is first observed and continuing until the timepoint at which the improvement is no longer observed

    Time frame: Up to 10 hours

  2. Change from predose value in the number of finger-taps at each timepoint

    Time frame: Up to 10 hours

Other outcomes

  1. Number of Participants with Adverse Events

    Time frame: Screening through end of study approximately 6 weeks per subject

  2. Maximum concentration (Cmax)

    Time frame: Up to 10 hours

  3. Area under the curve (AUC)

    Time frame: Up to 10 hours

07

Study locations

11 sites
  • Muhammad Ali Movement Disorder Center (MAMDC)
    Phoenix, Arizona 85013, United States
  • Clinical Trials, Inc.
    Little Rock, Arkansas 72205, United States
  • The Parkinson's and Movement Disorder Institute
    Fountain Valley, California 92708, United States
  • Parkinson's Disease and Movement Disorders Center of Boca Raton
    Boca Raton, Florida 33486, United States
  • Collier Neurologic Specialists
    Naples, Florida 34102, United States
  • University of South Florida Parkinson's Disease and Movement Disorder Center
    Tampa, Florida 33613, United States
  • Georgia Regents University
    Augusta, Georgia 30912, United States
  • QUEST Research Institute
    Farmington Hills, Michigan 48334, United States
  • Duke University Movement Disorders Clinic
    Durham, North Carolina 27705, United States
  • University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • Premier Clinical Research
    Spokane, Washington 99202, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2015, a primary completion of Aug 2016 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2014
First posted
Oct 22, 2014
Start
Nov 2015
Primary completionActual
Aug 2016
CompletionActual
Aug 2016
Results delay requested
Sep 7, 2017
Last update
Nov 6, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02271503
Responsible party
Sponsor
First posted
Oct 22, 2014
Start date
Nov 2015
Primary completion
Aug 2016
Completion
Aug 2016
Last update
Nov 6, 2019

Study contacts

Impax Study Director
study director · Impax Laboratories, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IPX203

Start the discussion